Psychedelics as potent anti-inflammatory therapeutics

Psychedelics have historically been studied for their profound effects on perception and consciousness, and research over many decades largely focused on central nervous system actions. Nichols and colleagues note that this brain-centric emphasis left peripheral biology relatively unexplored, even though the principal molecular target of classic psychedelics, the serotonin 2A receptor (5-HT2A), is widely expressed across tissues. Earlier physiological work had also shown that serotonin can be pro-inflammatory at sites of tissue injury and inflammation, and that 5-HT2A antagonists can block some of those pro-inflammatory effects. This paper presents a narrative review of work that identifies certain psychedelics as potent peripheral anti-inflammatories and immunomodulators. The aim is to describe the discovery pathway from in vitro assays to animal disease models, to report key efficacy and selectivity findings, and to outline translational implications including the possibility of developing sub‑behavioural or peripherally restricted 5-HT2A agonists for inflammatory diseases.

The paper synthesises a series of preclinical experimental approaches rather than reporting a single prospective trial. In vitro work used primary rat aortic smooth muscle (RASM) cells stimulated with the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-α) to measure induction of proinflammatory genes (for example IL6, VCAM1, ICAM1) and to determine concentration–response relationships for psychedelics. Receptor-selective antagonists were applied in some assays to test involvement of 5-HT2A versus other 5-HT2 subtypes. Several in vivo paradigms were described. An acute systemic inflammation model gave mice TNF-α i.p., with (R)-DOI administered intraperitoneally 30 minutes beforehand at low systemic doses (0.01, 0.1, 0.3 mg/kg); tissues were collected five hours later to measure mRNA and protein biomarkers in aortic arch, small intestine and plasma. A chronic cardiovascular/metabolic disease model used ApoE knockout mice fed a high-fat, high-cholesterol diet for 16 weeks with implanted osmotic minipumps to deliver continuous low systemic (R)-DOI (reported steady-state concentration Css = 0.515 ± 0.2 ng/ml). Outcomes included vascular inflammatory biomarkers, total cholesterol and glucose homeostasis. Allergic asthma models included both acute prophylactic and chronic paradigms. Sensitisation used ovalbumin (OVA) injections and subsequent nebulised OVA exposures to induce pulmonary inflammation, mucus overproduction and airway hyperresponsiveness. Prophylactic treatment was delivered 30 minutes prior to OVA exposure by nebulisation (nose-only) or i.p. injection. Primary physiological readouts used whole body plethysmography (WBP) measuring enhanced pause (PenH) as a proxy for airway hyperresponsiveness; cellular and molecular endpoints included Th2 cell recruitment, eosinophilia, and specific cytokine mRNA levels. The investigators screened a panel of ~25 psychedelics from phenethylamine, tryptamine and ergoline classes to compare routes, potencies and chemotype effects. Where reported, key pharmacological potency metrics were given (for example EC50/IC50 values). However, the extracted text does not consistently report sample sizes, specific statistical tests, or full methodological detail for all experiments; several efficacy claims are described as unpublished data.

In vitro, (R)-DOI showed very high anti-inflammatory potency in RASM cells stimulated with TNF-α, with an EC50 of approximately 20 picomolar for preventing induction of proinflammatory cytokines and adhesion molecules (IL6, VCAM1, ICAM1). By comparison the authors note corticosteroids act at low nanomolar concentrations at glucocorticoid receptors, indicating (R)-DOI was roughly 500x more potent at its target in these assays. Pharmacological blockade implicated 5-HT2A receptor activation as the mediator of the anti-inflammatory effect. Dose–response comparisons suggested that behavioural potency and anti-inflammatory potency are not closely linked: LSD, while behaviourally potent, was a comparatively weak anti-inflammatory (IC50 ≈ 30 nM), whereas other compounds including psilocin and (R)-DOI were highly potent. In vivo acute TNF-α challenge experiments demonstrated significant reductions up to complete suppression of TNF-α-mediated inflammation in tissues including aortic arch, small intestine and plasma after low systemic (R)-DOI doses (0.01–0.3 mg/kg i.p.). In some tissues maximal effects were seen at the lowest dose tested. These anti-inflammatory effects occurred at doses well below known behavioural thresholds; for instance, the minimal reported dose for a head‑twitch response for (R)-DOI is 0.3 mg/kg while maximal intestinal effects were observed at 0.01 mg/kg. In the ApoE–/– atherosclerosis model, continuous sub‑behavioural (R)-DOI exposure over 16 weeks suppressed proinflammatory mRNA in the aortic arch, lowered circulating total cholesterol and normalised glucose homeostasis. The mechanism for the metabolic effects was not determined in the extracted text. Importantly, the pattern of suppression was selective rather than globally immunosuppressive: certain proinflammatory markers (for example Cx3cl1) were unaffected, and for markers that were reduced their expression returned to baseline rather than being driven below control levels. In allergic asthma paradigms, prophylactic nebulised or systemic (R)-DOI prevented pulmonary inflammation, goblet cell hyperplasia/mucus overproduction, and normalised breathing mechanics. These protective effects were associated with reduced Th2 recruitment and eosinophilia, and specific cytokine mRNAs (IL6, IL1b, GMCSF, IL5) were blocked while others (IL4) were not. The reported IC50 in the prophylactic paradigm was ~0.005 mg/kg, more than 50x below the behavioural threshold. Psilocin exhibited similar potency to (R)-DOI. A screening panel of 25 psychedelics showed heterogeneity: LSD was only partially efficacious, while DMT and 5‑MeO‑DMT lacked measurable anti-inflammatory activity in the asthma model. The authors inferred a phenethylamine pharmacophore (2,5‑dimethoxyamphetamine core) for anti-inflammatory activity and proposed functional selectivity at 5-HT2A underlies differential effects on downstream signalling. Rescue experiments aimed at treating established inflammation were reported (some as unpublished): (R)-DOI delivered by inhalation several hours prior to testing attenuated T-cell–mediated inflammation and normalised airway hyperresponsiveness. In a chronic mouse model that produced persistent pulmonary fibrosis and airway remodelling, (R)-DOI given by inhalation reversed mucus overproduction and inflammation and produced a reported 70% reduction in collagen deposition and fibrosis.

Nichols frames these findings as demonstrating that certain psychedelics constitute a novel class of small molecule, highly bioavailable anti-inflammatory agents that can be steroid sparing and effective at sub‑behavioural doses. The wide tissue distribution of 5-HT2A receptors provided a mechanistic rationale for peripheral action, and receptor pharmacology experiments supported 5-HT2A agonism as central to the observed immunomodulatory effects. The selective pattern of cytokine and chemokine suppression led the investigators to emphasise that these compounds do not act as broad-spectrum immunosuppressants; instead they appear to modulate discrete components of inflammatory responses, a profile the authors suggest may reduce risks such as opportunistic infection that accompany global immunosuppression. The paper positions these preclinical results as opening translational opportunities for inflammatory and metabolic diseases where steroids are contraindicated or ineffective, and for conditions such as severe asthma and atherosclerosis. The authors note the prospect of designing next-generation molecules that retain peripheral anti-inflammatory efficacy while minimising behavioural effects—either by engineering functional selectivity at 5-HT2A to favour anti-inflammatory signalling, or by restricting blood–brain barrier penetration. They also highlight observed metabolic benefits (lowered cholesterol, normalised glucose) as intriguing but mechanistically unexplained findings that require further study. Limitations acknowledged in the extracted text include that some efficacy data are described as unpublished and that mechanisms underlying certain systemic effects remain to be elucidated. The paper therefore calls for additional mechanistic investigation and further preclinical development to define safety, dosing windows, and the potential for human translation.